Drugs Made In America Acquisition Rights Total Assets

Drugs Made In America Acquisition Rights (DMAAR) currently reports a total assets of $150M as of June 2026. That compares with $240M in the prior-year period — down 37.5% year over year. Use the charts on this page to explore Drugs Made In America Acquisition Rights's total assets history and peer comparisons.

Drugs Made In America Acquisition Rights's total assets decreased from $240M to $150M — a 37.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Drugs Made In America Acquisition Rights reported $150M in total assets as of June 2026. That compares with $240M in the prior-year period — down 37.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Drugs Made In America Acquisition Rights, and consider following DMAAR for alerts when major investors trade the stock.